Alice T Shaw

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Alice T Shaw
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 368:2385-94. 2013
  2. pmc ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
  3. pmc Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
  4. ncbi request reprint Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
  5. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
  6. doi request reprint Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
  7. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
  8. pmc Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
  9. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
  10. pmc ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012

Detail Information

Publications35

  1. doi request reprint Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Alice T Shaw
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 368:2385-94. 2013
    ..Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown...
  2. pmc ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
    ..In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers...
  3. pmc Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
    ....
  4. ncbi request reprint Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
    ..The application of innovative technologies to accurate mouse models promises to accelerate the discovery of new molecular targets and imaging biomarkers for the early detection of lung cancer...
  5. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
    ....
  6. doi request reprint Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
    ..Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the molecular basis for the development of resistance...
  7. pmc ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 19:4273-81. 2013
    ..Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naïve and crizotinib-resistant cancers...
  8. pmc Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
    ....
  9. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  10. pmc ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012
    ..Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement...
  11. doi request reprint Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    Pasi A Janne
    Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 14:38-47. 2013
    ..We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC...
  12. pmc A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    ..This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer...
  13. ncbi request reprint Crizotinib and testing for ALK
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Natl Compr Canc Netw 9:1335-41. 2011
    ....
  14. pmc Patient-derived models of acquired resistance can identify effective drug combinations for cancer
    Adam S Crystal
    Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA
    Science 346:1480-6. 2014
    ..With further refinements, this strategy could help direct therapeutic choices for individual patients. ..
  15. pmc Acquired resistance to crizotinib from a mutation in CD74-ROS1
    Mark M Awad
    Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 368:2395-401. 2013
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  16. doi request reprint Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Adam S Crystal
    Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 18:4479-81. 2012
    ..The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic...
  17. pmc Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
    ..Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease...
  18. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  19. pmc Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts Department of Medicine, Harvard Medical School, Boston, Massachusetts Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 20:5686-96. 2014
    ..As patients still relapse even on these next-generation ALK-TKIs, we examined mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance...
  20. pmc The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
    Luc Friboulet
    Authors Affiliations Massachusetts General Hospital Cancer Center Department of Medicine, Harvard Medical School, Boston, Massachusetts Genomics Institute of the Novartis Research Foundation, San Diego, California Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanAuthors Affiliations Massachusetts General Hospital Cancer Center Department of Medicine, Harvard Medical School, Boston, Massachusetts Genomics Institute of the Novartis Research Foundation, San Diego, California Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer Discov 4:662-73. 2014
    ..Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clinical data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease...
  21. pmc Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 108:7535-40. 2011
    ..Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations...
  22. doi request reprint The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer
    Justin F Gainor
    Departments of Medicine, Neurosurgery, Massachusetts General Hospital Cancer Center, Boston, Massachusetts and Department of Medicine, University of California, Irvine, Orange, California
    J Thorac Oncol 8:1570-3. 2013
    ....
  23. doi request reprint Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer
    Fiona Blackhall
    Department of Medical Oncology, Institute of Cancer Sciences, Manchester University, and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom Department of internal medicine, Seoul National University Hospital, Seoul, Korea Department of Thoracic Oncology, Institut Gustave Roussy, Villejuif, France National Cancer Center Hospital, Tokyo, Japan Division of Translational and Clinical Research, Center for Lung Cancer, National Cancer Center, Goyang, South Korea Clinical Development, Pfizer Oncology, La Jolla, CA Biostatistics, Pfizer Global Innovative Pharma Business, New York, NY Global Outcomes and Evidence, Pfizer Oncology, New York, NY Department of Oncology, McGill University Health Centre, Montreal, Canada and Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
    J Thorac Oncol 9:1625-33. 2014
    ....
  24. doi request reprint The new kid on the block: RET in lung cancer
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Discov 3:604-6. 2013
    ..In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer...
  25. pmc Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
    Justin F Gainor
    From the Massachusetts General Hospital Cancer Center, Boston, MA
    J Clin Oncol 31:3987-96. 2013
    ....
  26. pmc Tyrosine kinase gene rearrangements in epithelial malignancies
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Nat Rev Cancer 13:772-87. 2013
    ..We discuss the clinical outcomes with targeted therapies and explore strategies to discover additional kinases that are activated by chromosomal rearrangements in solid tumours. ..
  27. ncbi request reprint New targets in advanced NSCLC: EML4-ALK
    Adam S Crystal
    Massachusetts General Hospital Cancer Center Center, Boston, MA 02114, USA
    Clin Adv Hematol Oncol 9:207-14. 2011
    ..Here we review the discovery of EML4-ALK, the development of clinical diagnostics for ALK rearrangements, the clinical epidemiology of lung cancers driven by EML4-ALK, and ongoing ALK inhibitor-based clinical trials...
  28. pmc Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, MA Department of Medicine, Medical University of South Carolina, Charleston, SC and Department of Neurology, Massachusetts General Hospital, Boston, MA
    J Thorac Oncol 10:232-6. 2015
    ..Currently, the optimal management of LM in ALK-positive patients remains poorly understood as these patients have been routinely excluded from clinical trials...
  29. pmc Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
    Kimberley S Mak
    Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts K S M Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts J F G Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts A N, K S O, H W, N C C, J S L, H A S Massachusetts General Hospital Cancer Center, Boston, Massachusetts L V S, A T S
    Neuro Oncol 17:296-302. 2015
    ..We determined the impact of genetic alterations in EGFR, ALK, or KRAS on survival after radiotherapy for brain metastases in non-small cell lung cancer (NSCLC)...
  30. pmc Novel targets in non-small cell lung cancer: ROS1 and RET fusions
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 18:865-75. 2013
    ..In this review, we summarize the molecular biology, clinical features, detection, and targeting of ROS1 and RET rearrangements in NSCLC. ..
  31. pmc Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
    Alice T Shaw
    Koch Institute for Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 108:8773-8. 2011
    ..Our findings establish the specific antitumor activity of lanperisone and reveal oxidative stress pathways as potential targets in Ras-mediated malignancies...
  32. doi request reprint Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib
    Mark M Awad
    Division of Medical Oncology and Division of Rheumatology, Allergy, and Immunology Department of Medicine, Massachusetts General Hospital, Boston, MA
    J Thorac Oncol 9:1726-8. 2014
    ..Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity. ..
  33. pmc Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
    Daniel Morgensztern
    Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri Departments of Medical Oncology and Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado UCLA Santa Monica Hematology Oncology, Santa Monica, California Division of Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut Massachusetts General Hospital Cancer Center, Boston, Massachusetts Department of Oncology, The University of Chicago Medicine, Chicago, Illinois Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia Memorial Sloan Kettering Cancer Center, New York, New York Division of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina Sarah Cannon Research Institute, Nashville, Tennessee The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas and Division of Medical Oncology, Ann Arbor 48109
    J Thorac Oncol 10:S1-63. 2015
    ..Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy. ..
  34. pmc Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies
    Christine M Lovly
    Authors Affiliations Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center, Nashville, Tennessee and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    Clin Cancer Res 20:2249-56. 2014
    ..We describe specific mechanisms of primary and acquired resistance and then review emerging strategies to delay or overcome drug resistance...
  35. pmc Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
    Alice T Shaw
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston 02114, USA
    Genes Dev 21:694-707. 2007
    ..These findings indicate that in the lung, Sprouty-2 plays a critical role in the regulation of oncogenic K-ras, and implicate counter-regulatory mechanisms in the pathogenesis of Ras-based disease...